Syros is dedicated to developing therapies that control the expression of genes with the aim of providing a profound and durable benefit for patients.
Our platform is based on a deep and integrated understanding of the regulatory genome, disease biology and small molecule drug discovery. We seek to maximize value for us and our partners by extending our gene control platform across multiple therapeutic areas and diseases. For our SY-1425 program, we hold commercial rights in the United States and Europe, and for all our unpartnered programs, we hold worldwide rights.
We have two strategic collaborations: one with Global Blood Therapeutics (GBT) to discover an oral medicine to increase the expression of fetal globin with the aim of providing a functional cure for patients with sickle cell disease and beta thalassemia; and the other with Incyte Corporation to identify and validate new therapeutic targets in myeloproliferative neoplasms (MPNs). The collaboration with GBT allows us to expand, and potentially speed, our ongoing effort in sickle cell disease and beta thalassemia, while the collaboration with Incyte allows us to leverage the promise of our platform to benefit patients with diseases beyond our current areas of focus.
We will continue to evaluate potential collaborations that maximize the potential of our platform and expand our geographic reach to bring transformative therapies to patients.
Contact us at email@example.com to learn more about partnership opportunities.